A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.

Qianfoshan Hospital

Status

Enrolling

Conditions

Carcinoma, Hepatocellular

Treatments

Other: Immunotherapy, targeted therapy.

Study type

Observational

Funder types

Other

Identifiers

NCT06205732

YXLL-KY-2023(145)

Details and patient eligibility

About

To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.

Full description

To evaluate the efficacy and safety of TACE combined with immunotherapy and targeted therapy in patients with intermediate and advanced liver cancer. Explore the factors affecting the prognosis of liver cancer treated with TACE combined with immunotherapy and targeted therapy and establish a specific individualized prognostic score and risk stratification model.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥18 years old, both men and women
primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings
patients with liver function Child-Pugh A or B (≤8 points)
BCLC stage B and stage C
expected survival time ≥8 weeks
patients with generally good performance status (ECOG PS score 0 or 1)

Exclusion criteria

The patient's key data is missing
liver metastatic cancer confirmed by histology or cytology
patients who interrupt treatment due to intolerance of adverse drug reactions
combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc.
combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation
study participants known to have mental illness
situations such as drug use or substance abuse